Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma

Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncomm...

Descripción completa

Detalles Bibliográficos
Autores principales: Panomuppakarn, Nathamon, Witoonpanich, Patamintita, Waisayarat, Jariya, Jiarpinitnun, Chuleeporn, Ativitavas, Touch, Ngamphaiboon, Nuttapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628208/
https://www.ncbi.nlm.nih.gov/pubmed/29026560
http://dx.doi.org/10.1002/ccr3.1123
_version_ 1783268835735896064
author Panomuppakarn, Nathamon
Witoonpanich, Patamintita
Waisayarat, Jariya
Jiarpinitnun, Chuleeporn
Ativitavas, Touch
Ngamphaiboon, Nuttapong
author_facet Panomuppakarn, Nathamon
Witoonpanich, Patamintita
Waisayarat, Jariya
Jiarpinitnun, Chuleeporn
Ativitavas, Touch
Ngamphaiboon, Nuttapong
author_sort Panomuppakarn, Nathamon
collection PubMed
description Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide.
format Online
Article
Text
id pubmed-5628208
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56282082017-10-12 Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma Panomuppakarn, Nathamon Witoonpanich, Patamintita Waisayarat, Jariya Jiarpinitnun, Chuleeporn Ativitavas, Touch Ngamphaiboon, Nuttapong Clin Case Rep Case Reports Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide. John Wiley and Sons Inc. 2017-08-24 /pmc/articles/PMC5628208/ /pubmed/29026560 http://dx.doi.org/10.1002/ccr3.1123 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Panomuppakarn, Nathamon
Witoonpanich, Patamintita
Waisayarat, Jariya
Jiarpinitnun, Chuleeporn
Ativitavas, Touch
Ngamphaiboon, Nuttapong
Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title_full Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title_fullStr Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title_full_unstemmed Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title_short Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
title_sort uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628208/
https://www.ncbi.nlm.nih.gov/pubmed/29026560
http://dx.doi.org/10.1002/ccr3.1123
work_keys_str_mv AT panomuppakarnnathamon uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma
AT witoonpanichpatamintita uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma
AT waisayaratjariya uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma
AT jiarpinitnunchuleeporn uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma
AT ativitavastouch uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma
AT ngamphaiboonnuttapong uncommonresponseofcisplatinandetoposidefortreatmentofadvancedmedullarythyroidcarcinoma

Ejemplares similares